The chemoprotective effect of anti-platelet agents on cancer incidence in people with non-alcoholic fatty liver disease (NAFLD): a retrospective cohort study

Anson, Matthew; Poon, Jun Shang; Henney, Alex E.; Riley, David; Ibarbaru, Gema H.; Sieberhagen, Cyril; Cuthbertson, Daniel J.; Alam, Uazman; Hydes, Theresa

doi:10.1186/s12916-024-03802-4

Table 3 Summary of outcomes stratified by sex for all antiplatelet users

From: The chemoprotective effect of anti-platelet agents on cancer incidence in people with non-alcoholic fatty liver disease (NAFLD): a retrospective cohort study

	Male (n = 35,630)					Female (n = 44,240)
	Sample size	Outcome (n)	HR (95% confidence interval)	p value	E value	Sample size	Outcome (n)	HR (95% confidence interval)	p value	E value
*All obesity-related cancers*^a
Antiplatelets	16,749	224	0.69 (0.58–0.82)	< 0.001	1.91	19,003	525	0.78 (0.70–0.88)	< 0.001	1.66
No antiplatelets	16,937	293	0.69 (0.58–0.82)	< 0.001	1.91	19,639	638	0.78 (0.70–0.88)	< 0.001	1.66
*Hepatocellular carcinoma*
Antiplatelets	17,589	43	0.49 (0.34–0.72)	< 0.001	2.66	21,967	44	0.68 (0.46–1.01)	0.053	1.00
No antiplatelets	17,667	78	0.49 (0.34–0.72)	< 0.001	2.66	22,035	60	0.68 (0.46–1.01)	0.053	1.00
*Colorectal carcinoma*
Antiplatelets	17,391	71	0.70 (0.52–0.96)	0.026	1.88	21,691	85	0.71 (0.54–0.94)	0.018	1.85
No antiplatelets	17,420	89	0.70 (0.52–0.96)	0.026	1.88	21,779	111	0.71 (0.54–0.94)	0.018	1.85
*Pancreatic carcinoma*
Antiplatelets	17,707	54	0.72 (0.50–1.03)	0.070	1.00	22,012	39	0.45 (0.31–0.66)	< 0.001	2.86
No antiplatelets	17,693	67	0.72 (0.50–1.03)	0.070	1.00	21,963	81	0.45 (0.31–0.66)	< 0.001	2.86
*Oesophageal carcinoma*
Antiplatelets	17,768	14	0.54 (0.28–1.05)	0.066	1.00	22,096	10^b	0.84 (0.36–1.98)	0.690	1.00
No antiplatelets	17,760	23	0.54 (0.28–1.05)	0.066	1.00	22,106	11	0.84 (0.36–1.98)	0.690	1.00
*Gastric carcinoma*
Antiplatelets	17,760	21	0.60 (0.35–1.05)	0.068	1.00	22,070	20	0.97 (0.52–1.83)	0.935	1.00
No antiplatelets	17,759	31	0.60 (0.35–1.05)	0.068	1.00	22,081	19	0.97 (0.52–1.83)	0.935	1.00
*Gallbladder carcinoma*
Antiplatelets	17,787	10^b	1.32 (0.22–7.91)	0.759	1.00	22,109	10^b	0.69 (0.24–2.00)	0.494	1.00
No antiplatelets	17,802	10^b	1.32 (0.22–7.91)	0.759	1.00	22,098	10^b	0.69 (0.24–2.00)	0.494	1.00
*Ovarian carcinoma*
Antiplatelets	N/A					21,921	58	0.87 (0.61–1.25)	0.443	1.00
No antiplatelets	N/A					21,932	61	0.87 (0.61–1.25)	0.443	1.00
*Uterine carcinoma*
Antiplatelets	N/A					21,685	93	0.75 (0.57–0.98)	0.034	1.74
No antiplatelets	N/A					21,715	114	0.75 (0.57–0.98)	0.034	1.74
*Breast carcinoma*
Antiplatelets	17,783	10^b	1.04 (0.32–3.41)	0.947	1.00	20,448	235	0.79 (0.66–0.94)	0.006	1.63
No antiplatelets	17,791	10^b	1.04 (0.32–3.41)	0.947	1.00	20,878	281	0.79 (0.66–0.94)	0.006	1.63
*Multiple myeloma*
Antiplatelets	17,689	25	0.85 (0.49–1.47)	0.553	1.00	10,755	36	0.98 (0.61–1.57)	0.934	1.00
No antiplatelets	17,754	26	0.85 (0.49–1.47)	0.553	1.00	10,799	34	0.98 (0.61–1.57)	0.934	1.00
*Thyroid carcinoma*
Antiplatelets	17,714	29	1.07 (0.62–1.83)	0.819	1.00	21,852	36	0.82 (0.52–1.28)	0.369	1.00
No antiplatelets	17,756	24	1.07 (0.62–1.83)	0.819	1.00	21,975	41	0.82 (0.52–1.28)	0.369	1.00

^aIndividuals were censored at the first coding of a constituent obesity-related malignancy composite outcome. The total number of individuals experiencing the composite outcome differ than that of the sum of the individual events because, to better ascertain the primary preventative effect of aspirin on all obesity-related malignancies, individuals with a history of any of the constituent events were excluded from analysis of the composite outcome
^bTriNetX implements several safeguards to minimise the risk of patient reidentification. To avoid the risk that a series of individual queries could identify small subsets of cohorts, when a query returns a patient count on an outcome where the patient count is ≤ 10 but greater than 0, the count is obfuscated to 10. The reported HR is calculated without this obfuscation present

Back to article page

ISSN: 1741-7015

Contact us

General enquiries: journalsubmissions@springernature.com

BMC Medicine

Contact us